Vaccines for cocaine abuse

Human Vaccines

Volumn 5, Issue 4, 2009, Pages 194-199

  Orson, Frank M ^a   Kinsey, Berma M ^a   Singh, Rana A K ^a   Wu, Yan ^a   Kosten, Thomas R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody; Cocaine; Conjugate; Immunization; Substance abuse; Vaccine

Indexed keywords

B LYMPHOCYTE ANTIBODY; COCAINE; COCAINE VACCINE; HAPTEN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; BINDING AFFINITY; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; LOW DRUG DOSE; NONHUMAN; REVIEW; SUBSTANCE ABUSE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTIBODIES; COCAINE; COCAINE-RELATED DISORDERS; HUMANS; VACCINES, CONJUGATE;

EID: 70349479174     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.4.7457     Document Type: Review

References (56)

1. Drug Related Crime. White House Office of National Drug Control Policy 2006.
2. de la Fuente L, Brugal MT, Domingo-Salvany A, Bravo MJ, Neira-Leon M, Barrio G. More than thirty years of illicit drugs in Spain: a bitter story with some messages for the future. Rev Esp Salud Publica 2006; 80:505-20.
3. Heimer R, Barbour R, Shaboltas AV, Hoffman IF, Kozlov AP. Spatial distribution of HIV prevalence and incidence among injection drugs users in St Petersburg: implications for HIV transmission. Aids 2008; 22:123-30.
4. Kermode M, Longleng V, Singh BC, Hocking J, Langkham B, Crofts N. My first time: initiation into injecting drug use in Manipur and Nagaland, north-east India. Harm Reduct J 2007; 4:19.
5. National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHA Publication No. SMA 06-4194, Rockville, MD.: Substance Abuse and Mental Health Services Administration 2006.
6. Caulkins JP, Rydell CP, Schwabe WL, Chiesa J. Mandatory Minimum Drug Sentences: Throwing Away the Key or the Taxpayers' Money?. Rand Corporation 1997; 217.
7. Results from the 2007 National Survey on Drug Use and Health: National Findings (NSDUH Series H-34, DHHS Publication No. SMA 08-4343), Rockville, MD.: Substance Abuse and Mental Health Services Administration 2008.
8. Johnston LD, O'Malley PM, Bachman JG, Schulenberg J. Overall, illicit drug use by American teens continues gradual decline in 2007. Ann Arbor, MI.: University of Michigan News Service 2007.
9. Dowling GJ, Weiss SRB, Condon TP. Drugs of abuse and the aging brain. Neuropsychopharmacology 2008; 33:209-18.
10. EMCDDA Annual report 2006. European Monitoring Centre for Drugs and Drug Addiction 2006.
11. Alterman AI, Rutherford MJ, Cacciola JS, McKay JR, Woody GE. Response to methadone maintenance and counseling in antisocial patients with and without major depression. J Nerv Ment Dis 1996; 184:695-702.
12. Joe GW, Simpson DD, Broome KM. Retention and patient engagement models for different treatment modalities in DATOS. Drug Alcohol Depend 1999; 57:113-25.
13. Satel SL, Kosten TR, Schuckit MA, Fischman MW. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry 1993; 150:695-704.
14. Simpson DD, Joe GW, Fletcher BW, Hubbard RL, Anglin MD. A national evaluation of treatment outcomes for cocaine dependence. Arch Gen Psychiatry 1999; 56:507-14.
15. Millson P, Challacombe L, Villeneuve PJ, Strike CJ, Fischer B, Myers T, et al. Reduction in injection-related HIV risk after 6 months in a low-threshold methadone treatment program. AIDS Educ Prev 2007; 19:124-36.
16. Liu ZM, Lu XX, Mu Y, Lian Z, Zhou WH. Epidemiological features of drug abusers in China. J Drug Abuse Prev Treat 2002; 8:27-30.
17. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration. J Anal Toxicol 2002; 26:382-92.
18. Orson FM, Kinsey BM, Singh RAK, Wu Y, Gardner T, Kosten TR. The future of vaccines in the management of addictive disorders. Curr Psychiatry Rep 2007; 9:381-7.
19. Stevens RH, Saxon A. Reduced in vitro production of anti-tetanus toxoid antibody after repeated in vivo immunization with tetanus toxoid. J Immunol 1979; 122:592-8.
20. Berzofsky JA, Berkower IJ, eds. Immunogenicity and Antigen Structure. New York: Raven Press 1989.
21. Padovan E. T-cell response in penicillin allergy. Clin Exp Allergy 1998; 28:33-6.
22. Deng SX, Bharat N, Fischman MC, Landry DW. Covalent modification of proteins by cocaine. Proc Natl Acad Sci USA 2002; 99:3412-6.
23. Hofbauer GF, Hafner J, Trueb RM. Urticarial vasculitis following cocaine use. Br J Dermatol 1999; 141:600-1.
24. Merkel PA, Koroshetz WJ, Irizarry MC, Cudkowicz ME. Cocaine-associated cerebral vasculitis. Semin Arthritis Rheum 1995; 25:172-83.
25. Hofbauer GF, Burg G, Nestle FO. Cocaine-related Stevens-Johnson syndrome. Dermatology 2000; 201:258-60.
26. MacPherson RD, Willcox C, Chow C, Wang A. Anaesthetist's responses to patients' self-reported drug allergies. Br J Anaesth 2006; 97:634-9.
27. Nasser SM, Ewan PW. Opiate-sensitivity: clinical characteristics and the role of skin prick testing. Clin Exp Allergy 2001; 31:1014-20.
28. Fox BS, Kantak KM, Edwards MA, Black KM, Bollinger BK, Botka AJ, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996; 2:1129-32.
29. Hrafnkelsdottir K, Valgeirsson J, Gizurarson S. Induction of protective and specific antibodies against cocaine by intranasal immunisation using a glyceride adjuvant. Biol Pharm Bull 2005; 28:1038-42.
30. Carrera MR, Ashley JA, Zhou B, Wirsching P, Koob GF, Janda KD. Cocaine vaccines: antibody protection against relapse in a rat model. Proc Natl Acad Sci USA 2000; 97:6202-6.
31. Kosten TR, Biegel D. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2002; 1:363-71.
32. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005; 58:158-64.
33. Balster RL, Schuster CR. Fixed-interval schedule of cocaine reinforcement: effect of dose and infusion duration. J Exp Anal Behav 1973; 20:119-29.
34. Barbet J, Rougon-Rapuzzi G, Cupo A, Delaage MA. Structural requirements for recognition of vasopressin by antibody; thermodynamic and kinetic characteristics of the interaction. Mol Immunol 1981; 18:439-46.
35. Smith TW, Skubitz KM. Kinetics in interactions between antibodies and haptens. Biochemistry 1975; 14:1496-502.
36. Day ED. Advanced Immunochemistry. New York: Wiley-Liss 1990.
37. Orson FM, Kinsey BM, Singh RAK, Wu Y, Gardner T, Kosten TR. Substance abuse vaccines. Annals N Y Acad Sci 2008; 1141:257-69.
38. Eisen HN. Immunology. New York: Harper & Row 1980.
39. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1984; 149:1034-5.
40. Eisen HN, Siskind GW. Variations in affinities of antibodies during the immune response. Biochemistry 1964; 3:996-1008.
41. Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry 2006; 63:324-31.
42. Schmidt DH, Kaufman BM, Butler VP. Persistence of hapten-antibody complexes in the circulation of immunized animals after a single intravenous injection of hapten. J Exp Med 1974; 139:278-94.
43. Norman AB, Tabet MR, Norman MK, Buesing WR, Pesce AJ, Ball WJ. A chimeric human/murine anticocaine monoclonal antibody inhibits the distribution of cocaine to the brain in mice. J Pharmacol Exp Ther 2007; 320:145-53.
44. Laurenzana EM, Byrnes-Blake KA, Milesi-Halle A, Gentry WB, Williams DK, Owens SM. Use of anti-(+)-methamphetamine monoclonal antibody to significantly alter (+)-methamphetamine and (+)-amphetamine disposition in rats. Drug Metab Dispos 2003; 31:1320-6.
45. Hill JH, Wainer BH, Fitch FW, Rothberg RM. Delayed clearance of morphine from the circulation of rabbits immunized with morphine-6-hemisuccinate bovine serum albumin. J Immunol 1975; 114:1363-8.
46. Borges CR, Roberts JC, Wilkins DG, Rollins DE. Cocaine, benzoylecgonine, amphetamine and N-acetylamphetamine binding to melanin subtypes. J Anal Toxicol 2003; 27:125-34.
47. Matsushita M, Hoffman TZ, Ashley JA, Zhou B, Wirsching P, Janda KD. Cocaine catalytic antibodies: the primary importance of linker effects. Bioorg Med Chem Lett 2001; 11:87-90.
48. Williams RH, Maggiore JA, Shah SM, Erickson TB, Negrusz A. Cocaine and its major metabolites in plasma and urine samples from patients in an urban emergency medicine setting. J Anal Toxicol 2000; 24:478-81.
49. Horne MK, Lee J, Chen F, Lanning K, Tomas D, Lawrence AJ. Long-term administration of cocaine or serotonin reuptake inhibitors results in anatomical and neurochemical changes in noradrenergic, dopaminergic and serotonin pathways. J Neurochem 2008; 106:1731-44.
50. George FR. Cocaine produces low dose locomotor depressant effects in mice. Psychopharmacology (Berl) 1989; 99:147-50.
51. George FR. Cocaine produces low dose locomotor depressant effects in NBR and F344 rats. Pharmacol Biochem Behav 1990; 37:795-8.
52. Carrera MR, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD. Suppression of psychoactive effects of cocaine by active immunization. Nature 1995; 378:727-30.
53. Kantak KM, Collins SL, Lipman EG, Bond J, Giovanoni K, Fox BS. Evaluation of anti-cocaine antibodies and a cocaine vaccine in a rat self-administration model. Psychopharmacology (Berl) 2000; 148:251-62.
54. Sofuoglu M, Dudish-Poulsen S, Brown SB, Hatsukami DK. Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine. Drug Alcohol Depend 2003; 69:273-82.
55. Haney M, Kosten TR. Therapeutic vaccines for substance dependence. Expert Rev Vaccines 2004; 3:11-8.
56. Kosten TR, Rosen M, Bond J, Settles M, Roberts JS, Shields J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002; 20:1196-204.